A multi-center, placebo-controlled, double blind multiple-ascending dose study in a leapfrog design to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2016
At a glance
- Drugs RG 7103 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Roche
- 26 Oct 2016 Status changed from completed to withdrawn prior to enrolment.
- 25 Mar 2010 Status changed from recruiting to completed as reported by Roche record.
- 18 Feb 2010 Planned number of patients changed from 30 to 35 as reported by ClinicalTrials.gov.